http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2639847-C2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_66924d767c9b09fb52ec39ade78e5f89
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-47
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-167
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-47
filingDate 2016-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2017-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7b49825a5664b1d9d2a56780dfd591c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6c36b3575ff46ade3ca9b6de8cbd9f2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c694fddb8a6ac73da3224aafadc1184
publicationDate 2017-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber RU-2639847-C2
titleOfInvention Method for lymphotropic therapy of donor skin wounds
abstract FIELD: medicine. n SUBSTANCE: method includes subcutaneous injection of free autodermoplasty 32 ED lidase diluted in 2 ml of a 2% solution of lidocaine 1 hour before the operation, then after 5-10 minutes 4 ml of etamzilate are administered 1 time per day. Then, after 24 hours, the injection course is carried out at the same spot according to the scheme: 32 units of lidase diluted in 2 ml of a 2% solution of lidocaine, then after 5-10 minutes 5 ml of actovegin is injected once every two days in the amount of 4 injections. n EFFECT: use of the invention allows to reduce intraoperative blood loss, contributes to the prevention of bleeding and formation of hematomas in the donor site wound area in the postoperative period, accelerates epithelization and formation of a more delicate scar. n 1 ex
priorityDate 2016-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2326657-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002082594-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2562319-C1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCR4J7Z9
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID66895
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP26831
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCB3EWP2
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP0CH89
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID772
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419535552
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID129630823
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCI0CME8
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID3827
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCJ3S820
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419492895
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ54699
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ08169
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3676
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID449279464
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP86274
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP49371
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID3827
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCW0HFN9
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCC0HKM3
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP86687
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID66000
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCI0CME7
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ9U6V9
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID66000
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCA3QVN6
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP15316
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP85841
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCA3QVN2
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419555252
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP86875

Total number of triples: 51.